Entities / Company
Biogen.
American multinational biotechnology company
- Reports this week
- 1
- Active events
- 1
- Connections
- 303
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
Biogen supplied a drug to the health service (HSE) on September 16, 2026.Some support1 report
-
Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Biogen executives spoke at a conference hosted by Wells Fargo on September 12, 2026.Some support1 report
-
Georgia Hart campaigns for the use of a Biogen drug within the UK's National Health Service (NHS) in England, situated within the broader European context.Some support1 report
-
Leaders from Bain & Company and Biogen discussed industry trends at a summit on September 8, 2026.Some support1 report
-
The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).Some support1 report
One to three months ago
-
Veeva Systems reported successful Q2 earnings while securing new CRM adoption deals with Eli Lilly and Biogen.Some support1 report
-
HSE and Biogen engaged on August 25, 2026, regarding drug reimbursement for rare diseases.Some support2 reports
-
Biogen provided a substantially improved financial offer on August 25, 2026.Well supported5 reports
-
A US company is manufacturing drugs for Irish citizens, with discussions underway regarding the future role of EU funding models.Some support1 report
-
Michael Ehlers, a former executive at Pfizer and Biogen, is noted, alongside Sanofi backing Formation Bio.Some support1 report
-
Biogen manufactures the drug Skyclarys, which has received approvals from both the EMA and the FDA. The company is also dealing with a high court challenge regarding a delay, while the HSE Drugs Group considers coverage.Some support1 report2 developments inside
-
Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.Some support1 report
-
AstraZeneca and Biogen are working to meet ambitious revenue targets.Some support1 report
-
Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.Some support2 reports
-
Maja Pedersen, who is involved in the current event, previously worked at Biogen.Some support1 report
-
Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.Well supported6 reports1 development inside
-
An article published on July 4, 2026, draws a parallel between the business operations of Nvidia and Biogen.Some support1 report1 development inside
-
Apellis acquisition bolsters the long-term pipeline, with the company aiming to achieve success comparable to Nvidia.Some support1 report
-
AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.Some support2 reports
-
Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.Some support1 report
-
Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.Well supported3 reports1 development inside
-
Biogen stock is traded on Nasdaq and requires filing with the SEC.Well supported4 reports2 developments inside
-
Biogen filed reports with the SEC regarding holdings, while institutional investors increased stock holdings and analyst reports influenced market perception.Some support2 reports
-
The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.Some support4 reports2 developments inside
-
Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.Well supported7 reports
-
Biogen shared efficacy data for the drug Diranersen on July 14, 2026.Some support2 reports
-
Teva Pharmaceutical Industries is competing with major players Bayer, Biogen, and Novartis in the aflibercept biosimilar market.Some support1 report1 development inside
-
Investment purchases span technology and biotech sectors.Some support1 report1 development inside
-
Representatives made various stock trades and analysts updated price targets for tech and biotech firms like Datadog, IBM, and Biogen.Some support2 reports
-
Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.Well supported4 reports
-
Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.Some support2 reports
-
Australian clinical trial models are attracting companies like Biogen as they eye European markets under FDA oversight.Some support1 report
-
Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.Some support5 reports
Gone quiet
No new reports in 90+ days-
Biogen highlights continued progress in its portfolio, including research into tau-targeting ASO for Alzheimer's.Some support1 report
-
Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.Some support3 reports2 developments inside
-
Biogen is associated with Cambridge, Mass.Some support2 reports
-
Biogen is expanding its portfolio through an acquisition of RayThera Inc., adding valuable immunology assets to its holdings.Well supported8 reports
-
Biogen enters into an exclusive license agreement for ALT-B4 technology with ALTEOGEN Inc., with operations conducted in the PRC and internationally.Some support1 report
-
An investigation has been announced in New York City involving the company Biogen.Some support1 report
-
Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.Some support2 reports
-
Sinclair and Biogen were analyzed as low-volatility stocks on July 11, 2025.Some support1 report
-
Biogen shipped Leqembi to China for inventory optimization.Some support1 report
-
Bayer and Biogen announced they were both adopting .med TLDs on August 12, 2025.Some support1 report
-
Biogen, Mitsubishi Tanabe Pharma, and Ionis Pharmaceuticals are highlighted as being at the forefront of innovation in the field of ALS.Some support1 report
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Some support2 reports12 developments inside
-
FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.Some support4 reports
-
A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.Speculative1 report
-
Personnel changes and employment history updates involving several executives across companies like TransUnion, Google, and Biogen.Speculative3 reports
-
Biogen's campaign won the Gold Lion award at Cannes and was subsequently shared on Meta.Speculative1 report
-
A meeting regarding SMA research and clinical care was held in Anaheim, involving Biogen.Speculative1 report1 development inside
-
Biogen announced on June 25, 2025, that it is developing treatments for spinal muscular atrophy (SMA) and has results from Cambridge to be presented at a meeting in Anaheim.Speculative1 report
-
A market report profiled key companies in the oligonucleotide synthesis market, including Danaher, Biogen, AstraZeneca, and others.Speculative1 report
-
Biogen is facing questions regarding its product expansion, manufacturing capacity, and competitive landscape in Europe and Brazil, involving leadership and financial institutions.Speculative1 report
-
Biogen acquired Reata Pharmaceuticals for $7.3 billion on June 26, 2025.Speculative1 report
-
Biogen's experimental treatment showed efficacy following a gene therapy developed by Novartis.Speculative1 report
-
Biogen is seeking approval for a higher dose of nusinersen after presenting clinical trial data.Speculative2 reports
No events began in the chosen period. Widen it, or reset.
Around Biogen this week
News at the entities that move Biogen most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Biogen
-
Freedom Capital TransactionalRating upgrades and restatements on ASML shares, including an upgrade from hold to strong-buy, were announced.Moves Biogen
-
Veeva Systems OperationalVeea Inc. is listed on the Nasdaq stock exchange, and Geode Capital Management LLC raised its stake in the company, filing with the SEC.Moves Biogen
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Biogen
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Biogen
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Biogen
Connections
The 40 strongest of 303, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Veeva Systems Operational
Biogen utilizes Veeva's Vault CRM platform for its ongoing operational needs.
-
FDA Structural
The FDA functions as the mandatory regulatory body responsible for approving and overseeing Biogen's drug development and market access.
-
Eisai Structural
Biogen and Eisai are formally partnered for the joint development, commercialization, and revenue sharing of the Alzheimer's drug Leqembi.
-
Reata Pharmaceuticals Structural
Biogen acquired Reata Pharmaceuticals, establishing Reata as a subsidiary of Biogen.
-
Freedom Capital Transactional
Freedom Capital upgraded Biogen shares/rating to strong-buy in a recorded market action.
-
Sage Therapeutics (United States) Operational
The companies maintain an ongoing operational partnership for Zurzuvae commercialization while simultaneously engaging in strategic competition and M&A attempts.
-
Royalty Pharma Structural
Royalty Pharma receives payments and holds royalty rights on Biogen's products, supplemented by an ongoing R&D funding partnership.
-
Michael McDonnell Structural
Michael McDonnell held the role of Chief Financial Officer for Biogen.
Show all 40 connections
-
AstraZeneca Operational
The two companies are actively competing in the market, facing pressure to meet ambitious revenue targets.
-
BioArctic Structural
A successful technology transfer led to a current, ongoing joint venture requiring shared financial reporting.
-
Donald Trump Operational
Political uncertainty and tariff threats drive Biogen's operational decisions, specifically manufacturing expansion.
-
Regeneron Pharmaceuticals Operational
Regeneron and Biogen are active competitors across ophthalmology, immunology, and oncology therapeutic areas.
-
AbbVie Operational
AbbVie and Biogen are identified as direct competitors and peers operating in the biotechnology and neuroscience markets.
-
HSE Transactional
HSE and Biogen are engaged in ongoing negotiations regarding drug access, supply, and financial reimbursement for rare disease treatments.
-
SEC Structural
Biogen is subject to mandatory regulatory oversight and reporting requirements by the SEC.
-
Securities and Exchange Commission Structural
Biogen operates under the mandatory oversight and reporting requirements of the Securities and Exchange Commission.
-
Nasdaq Structural
Biogen is a publicly traded company listed on the Nasdaq stock exchange.
-
Michael Ehlers Structural
Michael Ehlers held a former executive position at Biogen.
-
Invesco Structural
Invesco maintains a large, ongoing investment position in Biogen.
-
United Therapeutics Operational
The two companies actively compete in the market as therapeutics stocks, with market performance and results influencing the other's standing.
-
representative Transactional
Representative purchased shares of Biogen in a historical transaction.
-
Teva Pharmaceutical Industries Ltd. Operational
Biogen and Teva are direct competitors in the aflibercept biosimilar market.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides investment ratings and market coverage on Biogen.
-
Morgan Stanley Operational
Morgan Stanley actively tracks Biogen and influences its market valuation through strategic reports and target price increases.
-
Health Service Executive Transactional
HSE negotiated funding approval and approved reimbursement for treatments provided by Biogen.
-
Moderna Operational
Moderna and Biogen are competitors operating in the therapeutics segment, with evidence of personnel exchange between the two companies.
-
Gilead Sciences Operational
The two companies are recognized as peers and actively compete within the therapeutics market.
-
Mizuho Transactional
Mizuho analysts raised their price target recommendation for Biogen, signaling market valuation.
-
Novavax Operational
The evidence indicates that both companies are direct competitors operating as peers within the therapeutics segment.
-
Novartis Operational
The companies actively compete in the health and wellness market, with their treatments being compared in efficacy studies.
-
MarketBeat Mentioned together
MarketBeat reports and tracks consensus ratings and financial data for Biogen.
-
Descartes Systems Group Operational
The relationship is evidenced by a single snapshot indicating that representatives of both companies compete in the market.
-
Vertex Pharmaceuticals Operational
Vertex Pharmaceuticals and Biogen are direct competitors, both developing and marketing therapies for serious diseases.
-
England Operational
Biogen is seeking procurement and market access for its drug within the National Health Service (NHS) system of England.
-
Ionis Pharmaceuticals Operational
Ionis Pharmaceuticals and Biogen maintain an active operational partnership for drug development and clinical trials.
-
Mike Structural
Mike served as the Chief Financial Officer of Biogen Inc.
-
TD Cowen Operational
TD Cowen, an investment firm, has issued analysis and raised the target price for Biogen stock.
-
Quest Diagnostics Operational
The relationship between Quest Diagnostics and Biogen is characterized by a recognized partnership structure.
-
IBM Mentioned together
The relationship is based on the shared context of their operations within the technology and biotechnology sectors.
-
Josh Brown Mentioned together
Josh Brown publicly highlighted Biogen as a stock recommendation.
History
Events by the month they beganSeptember 2026
8 events- Wyatt Gotbetter was appointed to several senior roles, including President of market access, involving PAREXEL, Cytel, and Biogen.
- Biogen supplied a drug to the health service (HSE) on September 16, 2026.
- Biogen, Eisai, and Morgan Stanley announced strategic shifts regarding the LEQEMBI treatment pathway simplification.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Biogen executives spoke at a conference hosted by Wells Fargo on September 12, 2026.
- Georgia Hart campaigns for the use of a Biogen drug within the UK's National Health Service (NHS) in England, situated within the broader European context.
- Leaders from Bain & Company and Biogen discussed industry trends at a summit on September 8, 2026.
- The FDA, Marathon Pharmaceuticals, and Biogen are leading the pre- and post-approval strategy and integrated medical launches for Multiple Sclerosis (MS).
August 2026
10 events- Veeva Systems reported successful Q2 earnings while securing new CRM adoption deals with Eli Lilly and Biogen.
- HSE and Biogen engaged on August 25, 2026, regarding drug reimbursement for rare diseases.
- Biogen provided a substantially improved financial offer on August 25, 2026.
- A US company is manufacturing drugs for Irish citizens, with discussions underway regarding the future role of EU funding models.
- Michael Ehlers, a former executive at Pfizer and Biogen, is noted, alongside Sanofi backing Formation Bio.
- Biogen manufactures the drug Skyclarys, which has received approvals from both the EMA and the FDA. The company is also dealing with a high court challenge regarding a delay, while the HSE Drugs Group considers coverage.
- Multiple legal appointments and JD degree completions were reported on August 11, 2026, involving several pharmaceutical companies.
- AstraZeneca and Biogen are working to meet ambitious revenue targets.
- Novavax, Nvidia, Biogen, and Amgen are involved in developments regarding specialized infrastructure and their shared status as peers in the therapeutics segment.
- Maja Pedersen, who is involved in the current event, previously worked at Biogen.
July 2026
10 events- An article published on July 4, 2026, draws a parallel between the business operations of Nvidia and Biogen.
- Apellis acquisition bolsters the long-term pipeline, with the company aiming to achieve success comparable to Nvidia.
- AbbVie, Incyte, and Biogen are noted as peers in the biotechnology segment after reporting their Q2 financial results.
- Biogen stock gain beat S&P 500 rise, while financing was needed for the acquisition of Apellis Pharmaceuticals.
- Biogen filed reports with the SEC regarding holdings, while institutional investors increased stock holdings and analyst reports influenced market perception.
- Biogen shared efficacy data for the drug Diranersen on July 14, 2026.
- Representatives made various stock trades and analysts updated price targets for tech and biotech firms like Datadog, IBM, and Biogen.
- Sanofi, Scribe Therapeutics, and Biogen are partnering on ALS gene therapy research, seeking a second research deal and initial public offering on Nasdaq.
- Australian clinical trial models are attracting companies like Biogen as they eye European markets under FDA oversight.
- Freedom Capital upgraded Biogen shares, and MarketBeat reported the consensus rating for the company.
Show 1 earlier month
June 2026
32 events- Biogen and Stoke Therapeutics jointly presented data on zorevunersen trials on September 2, 2025.
- Biogen, Eisai, and BioArctic announced the joint commercialization of lecanemab for Alzheimer's treatment.
- Biogen stock is traded on Nasdaq and requires filing with the SEC.
- The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
- Biogen and Eisai received FDA approval for a new drug formulation aimed at Alzheimer's disease.
- Teva Pharmaceutical Industries is competing with major players Bayer, Biogen, and Novartis in the aflibercept biosimilar market.
- Investment purchases span technology and biotech sectors.
- Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.
- Biogen highlights continued progress in its portfolio, including research into tau-targeting ASO for Alzheimer's.
- Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.
- Biogen is associated with Cambridge, Mass.
- Biogen is expanding its portfolio through an acquisition of RayThera Inc., adding valuable immunology assets to its holdings.
- Biogen enters into an exclusive license agreement for ALT-B4 technology with ALTEOGEN Inc., with operations conducted in the PRC and internationally.
- An investigation has been announced in New York City involving the company Biogen.
- Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.
- Sinclair and Biogen were analyzed as low-volatility stocks on July 11, 2025.
- Biogen shipped Leqembi to China for inventory optimization.
- Bayer and Biogen announced they were both adopting .med TLDs on August 12, 2025.
- Biogen, Mitsubishi Tanabe Pharma, and Ionis Pharmaceuticals are highlighted as being at the forefront of innovation in the field of ALS.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
- FDA approved BYOOVIZ as the first ophthalmology biosimilar, leading to a commercial rights transfer from Biogen to Harrow.
- A gene therapy for Friedreich ataxia has been designated as an Orphan Drug, Fast Track, and Rare Pediatric Disease.
- Personnel changes and employment history updates involving several executives across companies like TransUnion, Google, and Biogen.
- Biogen's campaign won the Gold Lion award at Cannes and was subsequently shared on Meta.
- A meeting regarding SMA research and clinical care was held in Anaheim, involving Biogen.
- Biogen announced on June 25, 2025, that it is developing treatments for spinal muscular atrophy (SMA) and has results from Cambridge to be presented at a meeting in Anaheim.
- A market report profiled key companies in the oligonucleotide synthesis market, including Danaher, Biogen, AstraZeneca, and others.
- Biogen is facing questions regarding its product expansion, manufacturing capacity, and competitive landscape in Europe and Brazil, involving leadership and financial institutions.
- Biogen acquired Reata Pharmaceuticals for $7.3 billion on June 26, 2025.
- Biogen's experimental treatment showed efficacy following a gene therapy developed by Novartis.
- Biogen is seeking approval for a higher dose of nusinersen after presenting clinical trial data.